In terms of the suitability of repurposed compounds to improve cancer immunotherapy, niclosamide in combination with PD-1/PD-L1 antibody has a synergistic anti-tumor effect in non-small cell lung cancer models through decreasing PD-L1 expression and promoting cytotoxic T cell activity [105]. Here, PDCD1 is linked to cancer.